Nevertheless, ~45% of early-stage breast cancer patients with hormone-receptor positive (ER+ and progesterone receptor+) disease do not respond to AIs (Ellis et al., 2001; Ellis and Ma, 2007) and up to 30% of patients will experience disease recurrence (Cuzick et al., 2010). This evidence concerns the gene ESR1 and breast carcinoma.